Clinical Trial Detail

NCT ID NCT03330847
Title To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

Therapies

Adavosertib + Olaparib

Olaparib

AZD6738 + Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST